Role of Digoxin-Like Immunoreactive Substance in the Pathogenesis of Transient Tachypnea of Newborn

Table 1

Demographic and clinical characteristics of TTN and control groups.

	TTN (𝑛=15)	Control (𝑛=15)	𝑃
Gestational age (week)	37.4±0.9	36.9±0.9	>0.05
(Mean ± SD) (min.–max.)	(36–39)	(35–38)
Birthweight (gram)	2883.3±182.4	2874.0±264	>0.05
(Mean ± SD) (min.–max.)	(2550–3120)	(2450–3420)
Delivery type (C/S) (𝑛%)	10 (66.67%)	10 (66.67%)	>0.05
Sex (male) (𝑛%)	9 (60%)	9 (60%)	>0.05
Apgar 1st (median) (min.–max.)	8 (7–10)	8 (7–10)	>0.05
Apgar 5th (median) (min.–max.)	9 (8–10)	9 (8–10)	>0.05
Arterial blood gas pH	7.32±0.06	7.34±0.04	>0.05
(Mean ± SD) (min.–max.)	(7.21–7.41)	(7.21–7.38)
Antenatal fluid to mother (mL/kg/hour)	9.2±6.8	13.0±7.5	>0.05
(Mean ± SD) (min.–max.)	(0–21)	(0–26)
Antenatal steroids (𝑛%)	8 (53.33%)	7 (46.6%)	>0.05
CRP (mg/dL)	0.39±0.23	0.44±0.19	>0.05
(Mean ± SD) (min.–max.)	(0.10–0.80)	(0.21–0.70)
Sepsis or pneumonia (𝑛%)	0	0	>0.05
Time of inclusion (hour)	14.86±2.23	16.13±2.67	>0.05
	(12–20)	(12–22)
RR0 (/min.ute)	72.2±9.0	47.6±2.9	<0.05
(Mean ± SD ) (min.–max.)	(60–90)	(44–54)
RRmax.(/min.ute)	87.0±9.6	52.0±2.5	<0.05
(Mean ± SD) (min.–max.)	(65–105)	(48–56)
Duration of tachypnea (DoT) (hour)	90.0±23.4	—	—
(Mean ± SD) (min.–max.)	(48–144)
Respiratory assistance (𝑛%)		—	—
Only O2 support	11 (73.3%)
nCPAP	2 (13.3%)
Mechanical ventilation	2 (13.3%)
Duration of hospitalization (hour)	148.2±47.8	30.2±11.4	<0.05
(Mean ± SD) (min.–max.)	(240–926)	(16–120)
Pneumothorax (𝑛%)	2 (13.3%)	—	—
DLIS1 (ng/mL)	0.66±0.37	0.24±0.20	<0.01
(Mean ± SD) (min.–max.)	(0–1.30)	(0–0.80)
DLIS7 (ng/mL)	0.27±0.21	0.11±0.11	<0.05
(Mean ± SD) (min.–max.)	(0–0.76)	(0–0.45)

S/C: caesarian section.
CRP: serum C reactive protein.
RR₀: respiratory rate on admission.
RR_max.: max.imum respiratory rate on follow-up.
CPAP: nasal continuous positive airway pressure.
DLIS₁: digitalis-like immunoreactive substance at the 1st day.
DLIS₇: digitalis-like immunoreactive substance at the 7th day.